



AMAG Pharmaceuticals, Inc.

From:	VP R&D at AMAG
Date:	01 November 2016

To Whom It May Concern:

I was the Vice President of Scientific Affairs for KV Pharmaceutical Company and Lumara Health, which included Clinical, Medical and Regulatory Affairs, prior to joining AMAG Pharmaceuticals as Vice President of Research and Development at AMAG Pharmaceuticals as part of its acquisition of Lumara Health. At KV and Lumara, we conducted numerous clinical trials on both branded and generic medications in both the US and Europe.

On several occasions we had the pleasure of working with Global Clinical Trials on studies in eastern Europe - involving sites in the Czech Republic, Hungary, Bulgaria, Romania, Ukraine, and Russia. We have provided return business to GCT in these geographies based on our satisfaction with their ability to conduct the trials on time, at a good quality, and at a reasonable cost.

I have met with many of their staff members in the US and Europe, and found them to be very professional, competent and also friendly colleagues with which to conduct business. They truly took on our project and our needs as their own. It was apparent that they spent time forming close collaborative relationships with the sites and also had good working knowledge of the local agency regulations and ethics committee procedures.

I would be happy to serve as a positive reference for GCT if they are being considered for future business. I would not hesitate to bring new projects to them in their areas of expertise in the geographies that they serve.

Vice President, Research and Development
AMAG Pharmaceuticals, Inc.
1100 Winter St.
Waltham, MA 02451